Abstract

This core service 9002, Pharmacokinetics and Assay Development, will provide developmental and analytical support to projects involving blood levels of anticancer agents used to treat cancer.
The specific aims i nclude developing sensitive and precise HPLC assays for: 1) new anticancer agents including taxotere, combretastatin a-4, azonafide EL- 53, imexon, adozelesin and a sulofenur analog to be tested in (Project 19) 2) new antitumor agents based on peptides for a) B-cell lymphomas or antagonists of matrilisin (Project 28) or b) for newly-identified inhibitors of cell-signalling molecules (Project 301) 3) characterize the AUC for three new agents used at LD50 doses in the mouse to apply the Collins dose-escalation method in humans (Project 19) and 4) characterize the clinical pharmacokinetics of DNA intercalators combined with cyclosporine A as a resistance chemomodulator in patients with refractory malignancies (Projects 29 + 19). Two analytical laboratories (Dr. Peng and Dr. Dorr) will work on these aims to provide rapid service to each of the projects. A pharmacokinetic data base will be developed for each agent by an interaction with the Biometry Core 9001. Overall, this core will help to guide the clinical development of new pharmacologic treatments of cancer.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA017094-20
Application #
5206879
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
1996
Total Cost
Indirect Cost

  Publications

Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35
Barrett, Harrison H; Alberts, David S; Woolfenden, James M et al. (2016) Therapy operating characteristic curves: tools for precision chemotherapy. J Med Imaging (Bellingham) 3:023502
Chang, Hae Ryung; Nam, Seungyoon; Kook, Myeong-Cherl et al. (2016) HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 65:19-32
Malm, Scott W; Hanke, Neale T; Gill, Alexander et al. (2015) The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J Exp Clin Cancer Res 34:31
Samulitis, Betty K; Pond, Kelvin W; Pond, Erika et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16:43-51
Landowski, Terry H; Gard, Jaime; Pond, Erika et al. (2014) Targeting integrin ?6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol Cancer Ther 13:1558-66
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Dragovich, T; Laheru, D; Dayyani, F et al. (2014) Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol 74:379-87
Exley, Mark A; Hand, Laura; O'Shea, Donal et al. (2014) Interplay between the immune system and adipose tissue in obesity. J Endocrinol 223:R41-8
Zhang, Xiaomeng; Pagel, Mark D; Baker, Amanda F et al. (2014) Reproducibility of magnetic resonance perfusion imaging. PLoS One 9:e89797

Showing the most recent 10 out of 314 publications